Delivery Order SPE2DB24D8002-SPE2DB24FJMSU

Award Date 8/7/24
Potential Completion Date 8/8/24
Potential Value $2.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract has a firm fixed price of $1,403.50 and a completion date of January 27, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) identified as SPE2DB24D8001, valued at $999,999,999.00, which allows Dakota Drug, Inc. to provide a comprehensive...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $7,640.80, is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a prescription pharmaceutical product. The award is associated with a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and Dakota Drug, Inc., identified as SPE2DB24D8001, valued at $999,999,999.00. This IDC is part of the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product, with a ceiling value of $2,133.91 and a period of performance through March 11, 2025. This contract is not set aside and is part of a larger Indefinite Delivery Contract (IDC) that Dakota Drug, Inc. holds with the DLA, identified as SPE2DB24D8001, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract, valued at $1,106.58, is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that Dakota Drug, Inc. holds with the DLA Troop Support Medical's ECAT...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,298.29, is for the delivery of the pharmaceutical product XULANE 150-35 MCG/DAY PATCH 3S. It is a firm fixed-price contract with a performance period extending to March 17, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical products to the U.S. Department of Defense, holding a significant Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The award, with a ceiling value of $2,147.04, is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S pharmaceutical products. The contract is a Firm Fixed Price Delivery Order with a period of performance through February 14, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical products to the U.S. Department of Defense, holding a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract has a firm fixed price pricing type, a ceiling value of $3,183.12, and a period of performance through January 7, 2025. Dakota Drug, Inc. is the prime contractor and there are no major subcontractors mentioned. This contract is not associated...
This federal contract award, identified as SPE2DB24D8002|SPE2DB25FJNJM, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product, with a ceiling value of $1,915.11 and a performance period ending on March 24, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001,...
This is a firm fixed-price delivery order contract awarded to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The contract, valued at $1,692.12, is for the supply of XULANE 150-35 MCG/DAY PATCH 3S. The contract is funded by the Defense Logistics Agency (DLA), a defense agency that provides medical supplies to the U.S. Armed Forces. Dakota Drug, Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,686.83, is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract has an ultimate completion date of March 25, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical and medical products to the U.S. Department of Defense, having been awarded a significant Indefinite...
  • SPE2DB24D8002
    Indefinite Delivery Contract
  • SPE2DB24D8002-SPE2DB24FJMSU
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract has a ceiling value of $2,554.39 and is for the delivery of XULANE 150-35 MCG/DAY PATCH 3S, a pharmaceutical product. The contract is a firm fixed-price delivery order and does not have a set-aside designation.

This award is associated with a larger Indefinite Delivery Contract (IDC) held by Dakota Drug, Inc. with the DLA, identified as SPE2DB24D8001. This single-award IDC, valued at $999,999,999.00, allows the company to provide a comprehensive range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations under the DLA Troop Support Medical's ECAT Generation V Program. The current delivery order is one of the specific contract actions issued against this IDC.

Generated 11/6/24, 9:15 AM